New probe facilitates ablation of a full range
of oncology and epilepsy targets, including in pediatrics,
leveraging the company's advanced laser and cooling technologies to
achieve wide range of ablation sizes and trajectory lengths
MINNETONKA, Minn., May 1, 2024
/PRNewswire/ -- Monteris Medical, the leader in image guided laser
interstitial thermal therapy (LITT), announced today the commercial
release of its NeuroBlate® NB3™ FullFire® 1.6mm laser probe, the
company's latest product line innovation for use with their
market-leading NeuroBlate System. The NB3 laser probe, featuring
the NeuroBlate System's patented cooling technology and
incorporating the latest advancements in laser fiber technology, is
the smallest laser probe commercially available for use in the
brain. The new NB3 probe is available in a single adjustable
length, continuing Monteris' established advantage of allowing all
laser probes to be used in multi-trajectory procedures while
offering intraoperative convenience to neurosurgeon users.
Additionally, the single NB3 probe device delivers economic value
to hospitals and streamlined inventory management with one
product.
The NB3 laser probe received FDA 510(k) clearance in
December 2023 and has been in limited
market release since February 2024 in
leading institutions across the United
States. Surgeons participating in the initial launch phase
used the probe across a comprehensive set of workflows, lesion
types, sizes, locations, target depths and patient profiles. Lesion
types include primary tumors, progressive metastatic lesions,
radiation necrosis and epileptogenic foci in both adult and
pediatric patients. Lesion sizes ablated during limited market
release have ranged from less than 10mm in diameter to nearly 30mm
in diameter and have included deep-seated targets and multiple
trajectory procedures.
The NB3 laser probe is designed to be used at varying power
settings ranging from six to 12 watts and is therefore engineered
to deliver small to large ablations, with some physicians
experiencing shorter ablation times.
Monteris will feature the NB3 laser probe and forthcoming
advanced thermography for the NeuroBlate System at the upcoming
American Academy of Neurological Surgeons (AANS) annual meeting in
Chicago, May 3-6, 2024, at the McCormick Place North
Building in Booth 854. NB3 will also be highlighted in the AANS
"Breakfast Bites" Educational Symposium on Saturday, May 4 at 7:30
a.m.
"We are thrilled to bring the highly anticipated NB3 laser probe
to our neurosurgeons and hospital system customers for use across a
broad spectrum of patient needs, including the pediatric LITT
population," said Martin J. Emerson,
president and chief executive officer of Monteris. "NB3, used in
combination with Monteris' best-in-class NeuroBlate software and
robotics, provides our neurosurgeon users the precision and
flexibility they demand for their patients. We expect the
forward-thinking engineering incorporated into NB3 will become the
platform for our future probe designs. In addition, our near-term
cadence of new software releases will put even greater options in
the hands of our neurosurgeon customers."
About Monteris and the NeuroBlate System
Monteris Medical is a privately held company that develops and
markets innovative MR-guided ablation systems to perform minimally
invasive, robotically controlled brain surgery, commonly referred
to as laser ablation, LITT (Laser Interstitial Thermal Therapy) or
SLA (Stereotactic Laser Ablation). The Monteris NeuroBlate
System is the only minimally invasive system that enables a robotic
interface for the precise and safe delivery of laser energy. The
Monteris Medical NeuroBlate System is a neurosurgical tool and is
intended for ablating intracranial soft tissue, including brain
structures such as brain tumors, radiation necrosis, and epileptic
foci (as identified by non-invasive and invasive neurodiagnostic
testing, including imaging). For more information, visit
monteris.com.
Media Contact:
Monteris Medical Corp.
Emily Smith
esmith@monteris.com
763-253-4710
Investor Contact:
Doug
Pahr
dpahr@monteris.com
763-253-4710
View original
content:https://www.prnewswire.com/news-releases/monteris-medical-announces-market-release-of-neuroblate-nb3-fullfire-1-6mm-laser-probe-smallest-commercially-available-laser-probe-for-use-in-the-brain-302132956.html
SOURCE Monteris Medical